Source: openalex · Origin: IT · Cinzia Parolini, Núria Mach · Frontiers in Cellular and Infection Microbiology · 2026-05-25
URL: https://doi.org/10.3389/fcimb.2026.1873260
AI rationale (4/5, tier: unclassified): Directly addresses microbiota-immune-barrier axis and IBD; editorial format limits mechanistic depth but core relevance established.
Over the past decade, the gut microbiota has emerged as one of the most powerful regulators of host homeostasis. No longer viewed as a passive collection of commensals, it is now recognized as a dynamic immunological and endocrine interface that shapes metabolism, immune function, and systemic inflammation from early life through disease. Dysbiosis-whether through altered microbial composition or disrupted metabolic output-has been implicated in a wide range of immune-mediated inflammatory diseases, including inflammatory bowel disease, diabetes, Together, these studies illustrate the breadth and depth of the microbiota-gut-immune axis, showing how microbial communities and their metabolites influence inflammation across the kidney, skin, intestine, and lungs (Figure 1). They collectively underscore the promise of microbiota-targeted strategies for understanding, diagnosing, and treating immune-mediated inflammatory diseases.Several new hypotheses emerge from this body of work. One is that specific immune cell subsetssuch as CD4⁺ T cells, or tissue-resident lymphocytes-may act as intermediaries that translate microbial signals into systemic inflammatory responses. Another is that microbial metabolites, particularly short-chain fatty acids and bile acid derivatives, may function as endocrine-like molecules, with effects shaped by host metabolic and hormonal status or by diet. A third hypothesis is that early dysbiosis signatures in diseases such as IBD or psoriasis may not simply reflect inflammation but could represent preclinical microbial shifts that predispose individuals to disease onset.Advancing the field will require integrating metagenomics, metabolomics, immunophenotyping, and host genetics and epigenetics into unified frameworks. It will also require expanding microbiota-based interventions beyond traditional probiotics and prebiotics toward synthetic bacterial communities, bacteriophage therapy, metabolite supplementation, and precision dietary strategies tailored to individual microbial and immunological profiles. The acetate supplementation study in this issue exemplifies how microbial metabolites can be leveraged therapeutically, opening the door to metabolite-based immunomodulation. Ultimately, the field must adopt a more integrative and personalized approach. Inter-individual variability in microbiota composition means that universal therapies are unlikely to succeed.In summary, this Research Topic offers a forward-looking view of how the gut microbiota shapes immune-related inflammatory diseases. By proposing new hypotheses, embracing multi-omics integration, and advancing toward personalized microbiota-based therapies, the field is poised to make transformative contributions to human health.